On November 3, 2026, SeaStar Medical Holding Corporation announced that the U.S. Food and Drug Administration (FDA) has confirmed that its QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled the necessary post-approval study requirements. This significant milestone allows the company to expand access to its QUELIMMUNE therapy for pediatric patients suffering from sepsis-associated acute kidney injury (AKI).

SeaStar Medical, which trades on the Nasdaq under the ticker symbols ICU and ICUCW, is a commercial-stage healthcare company based in Denver, Colorado. The company focuses on innovative treatments for critically ill patients facing organ failure. The FDA's decision is expected to enhance the potential life-saving benefits of QUELIMMUNE, which has shown promising results in treating pediatric patients with life-threatening conditions.

According to the filing, SeaStar Medical expressed gratitude for the FDA's determination. CEO Eric Schlorff stated, “We believe this decision will be a win-win for patients, their families, health care providers, and the overall health care system.” The QUELIMMUNE therapy has been associated with a significantly improved survival rate among critically ill children, who typically face a survival rate of about 50% with traditional care.

The filing highlights that results from the SAVE Registry were recently presented at ASN Kidney Week 2026, showcasing a clinically meaningful and statistically significant improvement in survival rates for patients treated with QUELIMMUNE. The data indicated a 90-day survival rate of 65.1% for QUELIMMUNE patients compared to 47.5% for those receiving standard care, demonstrating the therapy's potential effectiveness.

SeaStar Medical's QUELIMMUNE therapy is designed for children weighing at least 10 kilograms and aged 22 years or younger who are on antibiotics and receiving renal replacement therapy (RRT) in an ICU setting. The FDA's decision now allows hospitals to implement this therapy without the research infrastructure previously required by the SAVE Registry, thereby broadening access to treatment for critically ill pediatric patients.

In addition to the immediate implications for patient care, this development may influence the surgical and medical instruments industry by highlighting the importance of innovative therapies for pediatric patients. SeaStar Medical plans to continue voluntary enrollment in the SAVE Registry at participating medical centers to gather further evidence regarding the use of QUELIMMUNE.

As SeaStar Medical moves forward, it will be crucial to monitor how this FDA decision impacts patient access and treatment outcomes in the pediatric healthcare landscape. The filing does not specify what happens next, but the company is poised to leverage this confirmation to enhance its market presence and improve patient care.